Abstract
TCL-275 Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients With Relapsed or Refractory T-Cell Lymphoma (TCL) With Survival Analysis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have